INTERPHEX 2013 Announces Conference Program - - BioPharm International


INTERPHEX 2013 Announces Conference Program

INTERPHEX 2013 New York

The INTERPHEX Conference Program, to be held Apr. 23–25, 2013, at the Javits Center in New York, New York, has been developed to span the pharmaceutical manufacturing life cycle. The conference tracks and accompanying sessions have been configured to reflect the project team environment firms use to usher products from development to commercial distribution, according to a Feb. 26, 2013, INTERPHEX press release.

The conference will feature a variety of programs from quality-by-design and process analytical technology tutorials to sound development of a design space. Industry thought leaders will provide insight from a variety of arenas including academia, consulting, and pharmaceutical manufacturing. All functional areas are addressed in five comprehensive session tracks: regulatory QA/QC, product development, facility and process design, manufacturing and packaging, and supply chain.

Pharmaceutical Technology will host two sessions. In a keynote address, Jim Miller, President, PharmSource Information Services, Inc. will discuss forces shaping the contract services industry in “Recalibrating the Pharmaceutical Services Opportunity”, scheduled for Wednesday, Apr. 24, at 9 am. In a panel discussion, “Lessons Learned: Successes and Challenges In Implementing Quality By Design,” manufacturing and regulatory experts will share their insight and practical experience in implementing QbD, including strategies for defining a design space, adaption of manufacturing processes, the feasibility for real-time release testing, and the keys to continuous process verification. The panel is scheduled for Wednesday, Apr. 24, at 10:15 am.

Other sessions include “Current Continuous Process Validation Program (CCVP) Following FDA Current Guidelines,” presented by Victor Hernandez, EMD Millipore, which will review how firms are frantically backfilling knowledge in order to maintain products throughout their lifecycle. Additionally, Robert Dream's session entitled “Biopharma’s Flexible Imperative” will discuss the new model biopharmaceutical facility, one far less rigid than earlier prototypes. Dream, from HDR Company LLC, will discuss external influences on the new flexible model, including the timely role of biodefense.

In other keynote sessions, Congressman Bill Cassidy’s, MD, (R-LA) presentation, “Policy Recommendations for Improving Patient Access to Drugs in Shortage,” will touch upon potential improvements to the current reimbursement system to avoid future drug shortages and Dr Rajesh Nair, president, Indegene will discuss “Reorganizing for the Future: Succeeding in the New Pharmaceutical Industry.”

Rounding out INTERPHEX’s educational component will be a series of Exhibit Hall Technology Floor Tours: OSD Technologies, Advanced Aseptic Technologies, Biomanufacturing Technologies, and Modular Construction Technologies. Tours will offer critical insights followed by a walking tour to select vendors showcasing the latest technology and equipment on the show floor.

blog comments powered by Disqus



FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here